The origins of oxidant stress in parkinson's disease and therapeutic strategies

Antioxidants and Redox Signaling

Volumn 14, Issue 7, 2011, Pages 1289-1301

  Surmeier, Dalton James ^a   Guzman, Jaime N ^a   Sanchez Padilla, Javier ^a   Goldberg, Joshua A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CALCIUM CHANNEL L TYPE; DIHYDROPYRIDINE DERIVATIVE; DJ 1 PROTEIN; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; OXIDOPAMINE; PARKIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN INDUCED PUTATIVE KINASE 1; ROTENONE; TOXIN; UNCLASSIFIED DRUG;

AGING; CELL STRESS; CYTOPLASM; DISEASE PREDISPOSITION; DOPAMINERGIC NERVE CELL; HUMAN; MITOCHONDRION; NERVE ENDING; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHENOTYPE; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SUBSTANTIA NIGRA PARS COMPACTA;

AGING; ANIMALS; BIOLOGICAL CLOCKS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM SIGNALING; CELL DEATH; HUMANS; ISRADIPINE; LOCUS COERULEUS; MITOCHONDRIA; OXIDATIVE STRESS; PARKINSON DISEASE; REACTIVE OXYGEN SPECIES; RISK FACTORS; SUBSTANTIA NIGRA;

ANIMALIA;

EID: 79952406815     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2010.3521     Document Type: Review

References (127)

1. Amini B, Clark JW, Jr., and Canavier CC. Calcium dynamics underlying pacemaker-like and burst firing oscillations in midbrain dopaminergic neurons: a computational study. J Neurophysiol 82: 2249-2261, 1999.
2. Andres-Mateos E, Perier C, Zhang L, Blanchard-Fillion B, Greco TM, Thomas B, Ko HS, Sasaki M, Ischiropoulos H, Przedborski S, Dawson TM, and Dawson VL. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci USA 104: 14807-14812, 2007. (Pubitemid 350003224)
3. Arbuthnott GW and Wickens J. Space, time and dopamine. Trends Neurosci 30: 62-69, 2007. (Pubitemid 46161843)
4. Backman L, Ginovart N, Dixon RA, Wahlin TB, Wahlin A, Halldin C, and Farde L. Age-related cognitive deficits mediated by changes in the striatal dopamine system. Am J Psychiatry 157: 635-637, 2000. (Pubitemid 30191207)
5. Beal MF. Aging, energy, and oxidative stress in neurode-generative diseases. Ann Neurol 38: 357-366, 1995.
6. Beal MF. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann Neurol 44: S110-S114, 1998. (Pubitemid 28423836)
7. Beal MF, Matthews RT, Tieleman A, and Shults CW. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3, tetrahydropyridine (MPTP) induced loss of striatal dopa-mine and dopaminergic axons in aged mice. Brain Res 783: 109-114, 1998. (Pubitemid 28131427)
8. Bean BP. Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state. Proc Natl Acad Sci USA 81: 6388-6392, 1984. (Pubitemid 15220843)
9. Becker C, Jick SS, and Meier CR. Use of antihypertensives and the risk of Parkinson disease. Neurology 70: 1438-1444, 2008. (Pubitemid 351521937)
10. Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, Jaros E, Hersheson JS, Betts J, Klopstock T, Taylor RW, and Turnbull DM. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 38: 515-517, 2006.
11. Bender A, Schwarzkopf RM, McMillan A, Krishnan KJ, Rieder G, Neumann M, Elstner M, Turnbull DM, and Klopstock T. Dopaminergic midbrain neurons are the prime target for mitochondrial DNA deletions. J Neurol 255: 1231-1235, 2008.
12. Berridge MJ, Lipp P, and Bootman MD. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 1: 11-21, 2000.
13. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, and Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3: 1301-1306, 2000.
14. Blythe SN, Wokosin D, Atherton JF, and Bevan MD. Cellular mechanisms underlying burst firing in substan-tia nigra dopamine neurons. J Neurosci 29: 15531-15541, 2009.
15. Bonci A, Grillner P, Mercuri NB, and Bernardi G. L-Type calcium channels mediate a slow excitatory synaptic transmission in rat midbrain dopaminergic neurons. J Neurosci 18: 6693-6703, 1998. (Pubitemid 28388001)
16. Boumezbeur F, Mason GF, de Graaf RA, Behar KL, Cline GW, Shulman GI, Rothman DL, and Petersen KF. Altered brain mitochondrial metabolism in healthy aging as assessed by in vivo magnetic resonance spectroscopy. J Cereb Blood Flow Metab 30: 211-221, 2010.
17. Braak H, Ghebremedhin E, Rub U, Bratzke H, and Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318: 121-134, 2004. (Pubitemid 39362633)
18. Burke RE, Dauer WT, and Vonsattel JP. A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol 64: 485-491, 2008.
19. Burlhis TM and Aghajanian GK. Pacemaker potentials of serotonergic dorsal raphe neurons: contribution of a low-threshold Ca2\+ conductance. Synapse 1: 582-588, 1987. (Pubitemid 18007839)
20. Calne DB and Langston JW. Aetiology of Parkinson's disease. Lancet 2: 1457-1459, 1983. (Pubitemid 14203375)
21. Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, Meredith GE, and Surmeier DJ. "Rejuvenation" protects neurons in mouse models of Parkinson's disease. Nature 447: 1081-1086, 2007. (Pubitemid 47014425)
22. Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, Seol JH, Yoo SJ, Hay BA, and Guo M. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441: 1162-1166, 2006. (Pubitemid 43990738)
23. Collier TJ, Lipton J, Daley BF, Palfi S, Chu Y, Sortwell C, Bakay RA, Sladek JR, Jr., and Kordower JH. Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis 26: 56-65, 2007. (Pubitemid 46436486)
24. Damier P, Hirsch EC, Agid Y, and Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122 (Pt 8): 1437-1448, 1999. (Pubitemid 29374122)
25. de Lau LM and Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 5: 525-535, 2006. (Pubitemid 44262284)
26. Deister CA, Teagarden MA, Wilson CJ, and Paladini CA. An intrinsic neuronal oscillator underlies dopaminergic neuron bursting. J Neurosci 29: 15888-15897, 2009.
27. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schi-fitto G, Siderowf A, and Tanner CM. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68: 384-386, 2007. (Pubitemid 46184217)
28. Eisenberg MJ, Brox A, and Bestawros AN. Calcium channel blockers: an update. Am J Med 116: 35-43, 2004. (Pubitemid 38050025)
29. Exner N, Treske B, Paquet D, Holmstrom K, Schiesling C, Gispert S, Carballocarbajal I, Berg D, Hoepken HH, Gasser T, Kruger R, Winklhofer KF, Vogel F, Reichert AS, Auburger G, Kahle PJ, Schmid B, and Haass C. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci 27: 12413-12418, 2007. (Pubitemid 350085485)
30. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 252 Suppl 4: IV37-IV42, 2005. (Pubitemid 41437719)
31. Fitton A and Benfield P. Isradipine. A review of its phar-macodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 40: 31-74, 1990.
32. Fronczek R, Overeem S, Lee SY, Hegeman IM, van Pelt J, van Duinen SG, Lammers GJ, and Swaab DF. Hypocretin (orexin) loss in Parkinson's disease. Brain 130: 1577-1585, 2007. (Pubitemid 47355929)
33. Galvin JE, Uryu K, Lee VM, and Trojanowski JQ. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc Natl Acad Sci USA 96: 13450-13455, 1999.
34. Gasser T. Mendelian forms of Parkinson's disease. Biochim Biophys Acta 1792: 587-596, 2009.
35. German DC, Manaye KF, Sonsalla PK, and Brooks BA. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindind28k-containing cells. Ann N Y Acad Sci 648: 42-62, 1992.
36. German DC, Manaye KF, White CL, 3rd, Woodward DJ, McIntire DD, Smith WK, Kalaria RN, and Mann DM. Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 32: 667-676, 1992.
37. Gibb WR and Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 54: 388-396, 1991.
38. Goldberg MS, Pisani A, Haburcak M, Vortherms TA, Ki-tada T, Costa C, Tong Y, Martella G, Tscherter A, Martins A, Bernardi G, Roth BL, Pothos EN, Calabresi P, and Shen J. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 45: 489-496, 2005. (Pubitemid 40249861)
39. Grace AA and Bunney BS. The control of firing pattern in nigral dopamine neurons: single spike firing. J Neurosci 4: 2866-2876, 1984. (Pubitemid 15224431)
40. GreenamyreJTand Hastings TG. Biomedicine. Parkinson's-divergent causes, convergent mechanisms. Science 304: 1120-1122, 2004. (Pubitemid 38661838)
41. Greenamyre JT and O'Brien CF. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch Neurol 48: 977-981, 1991.
42. Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, and Pallanck LJ. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci USA 100: 4078-4083, 2003. (Pubitemid 36418160)
43. Guzman JN, Sanchez-Padilla J, Chan CS, and Surmeier DJ. Robust pacemaking in substantia nigra dopaminergic neurons. J Neurosci 29: 11011-11019, 2009.
44. Harman D. The biologic clock: the mitochondria? J Am Geriatr Soc 20: 145-147, 1972.
45. Harman D. The free radical theory of aging. Antioxid Redox Signal 5: 557-561, 2003. (Pubitemid 37315142)
46. Hartmann A, Hunot S, and Hirsch EC. Inflammation and dopaminergic neuronal loss in Parkinson's disease: a complex matter. Exp Neurol 184: 561-564, 2003. (Pubitemid 38182787)
47. Hawkes CH, Del Tredici K, and Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 33: 599-614, 2007. (Pubitemid 350076090)
48. Hirsch EC and Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8: 382-397, 2009.
49. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev 18: 925-964, 1966.
50. Huisman E, Uylings HB, and Hoogland PV. Gender-related changes in increase of dopaminergic neurons in the olfactory bulb of Parkinson's disease patients. Mov Disord 23: 1407-1413, 2008.
51. Hung AY and Schwarzschild MA. Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility? Curr Opin Neurol 20: 477-483, 2007. (Pubitemid 47051997)
52. Hunot S and Hirsch EC. Neuroinflammatory processes in Parkinson's disease. Ann Neurol 53 Suppl 3: S49-S58; discussion S58-S60, 2003.
53. Hunot S, Vila M, Teismann P, Davis RJ, Hirsch EC, Przedborski S, Rakic P, and Flavell RA. JNK-mediated induction of cyclooxygenase 2 is required for neurodegen-eration in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 101: 665-670, 2004. (Pubitemid 38084694)
54. Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F, Neumeyer J, Margouleff C, Babchyck B, Zanzi I, and Eidelberg D. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP=SPECT and fluorine-18-FDOPA= PET. J Nucl Med 37: 1760-1765, 1996. (Pubitemid 26378356)
55. Ito H, Goto S, Sakamoto S, and Hirano A. Calbindind28k in the basal ganglia of patients with parkinsonism. Ann Neurol 32: 543-550, 1992.
56. Jellinger KA. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys Acta 1792: 730-740, 2009.
57. Jellinger KA. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol 116: 1-16, 2008.
58. Kahle PJ, Waak J, and Gasser T. DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. Free Radic Biol Med 47: 1354-1361, 2009.
59. Kamel F, Tanner C, Umbach D, Hoppin J, Alavanja M, Blair A, Comyns K, Goldman S, Korell M, Langston J, Ross G, and Sandler D. Pesticide exposure and self-reported Parkinson's disease in the agricultural health study. Am J Epidemiol 165: 364-374, 2007.
60. Kanaan NM, Kordower JH, and Collier TJ. Age-related accumulation of Marinesco bodies and lipofuscin in rhesus monkey midbrain dopamine neurons: relevance to selective neuronal vulnerability. J Comp Neurol 502: 683-700, 2007. (Pubitemid 46732491)
61. Kanaan NM, Kordower JH, and Collier TJ. Age-related changes in dopamine transporters and accumulation of 3-nitrotyrosine in rhesus monkey midbrain dopamine neurons: relevance in selective neuronal vulnerability to degeneration. Eur J Neurosci 27: 3205-3215, 2008. (Pubitemid 351847325)
62. Kish SJ, Shannak K, and Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 318: 876-880, 1988. (Pubitemid 18090271)
63. Kitada T, Pisani A, Porter DR, Yamaguchi H, Tscherter A, Martella G, Bonsi P, Zhang C, Pothos EN, and Shen J. Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc Natl Acad Sci USA 104: 11441-11446, 2007. (Pubitemid 47175159)
64. Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, Mueller G, Wermer M, Kaddurah-Daouk R, and Beal MF. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 5: 347-350, 1999. (Pubitemid 29124375)
65. Kordower JH, Chu Y, Hauser RA, Freeman TB, and Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 14: 504-506, 2008. (Pubitemid 351655212)
66. 2\+ channels activating at negative voltages. J Biol Chem 276: 22100-22106, 2001.
67. Kupsch A, Sautter J, Schwarz J, Riederer P, Gerlach M, and Oertel WH. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res 741: 185-196, 1996. (Pubitemid 26426315)
68. Lees AJ, Hardy J, and Revesz T. Parkinson's disease. Lancet 373: 2055-2066, 2009.
69. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Bjorklund A, Widner H, Revesz T, Lindvall O, and Brundin P. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-tograft disease propagation. Nat Med 14: 501-503, 2008. (Pubitemid 351655211)
70. Li Y, Gao XB, Sakurai T, and van den Pol AN. Hypocre-tin=orexin excites hypocretin neurons via a local glutamate neuron-A potential mechanism for orchestrating the hy-pothalamic arousal system. Neuron 36: 1169-1181, 2002. (Pubitemid 36044516)
71. Liang CL, Wang TT, Luby-Phelps K, and German DC. Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease. Exp Neurol 203: 370-380, 2007. (Pubitemid 46149588)
72. Magyar K and Szende B. Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neurotoxicology 25: 233-242, 2004. (Pubitemid 38054334)
73. Mannhold R, Rekker RF, Sonntag C, ter Laak AM, Dross K, and Polymeropoulos EE. Comparative evaluation of the predictive power of calculation procedures for molecular lipophilicity. J Pharm Sci 84: 1410-1419, 1995.
74. Matsuda W, Furuta T, Nakamura KC, Hioki H, Fujiyama F, Arai R, and Kaneko T. Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J Neurosci 29: 444-453, 2009.
75. Matzuk MM and Saper CB. Preservation of hypothalamic dopaminergic neurons in Parkinson's disease. Ann Neurol 18: 552-555, 1985. (Pubitemid 16258089)
76. McCormack AL, Di Monte DA, Delfani K, Irwin I, De-Lanney LE, Langston WJ, and Janson AM. Aging of the nigrostriatal system in the squirrel monkey. J Comp Neurol 471: 387-395, 2004. (Pubitemid 38401739)
77. Mendez I, Vinuela A, Astradsson A, Mukhida K, Hallett P, Robertson H, Tierney T, Holness R, Dagher A, Trojanowski JQ, and Isacson O. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med 14: 507-509, 2008. (Pubitemid 351655215)
78. Mercuri NB, Bonci A, Calabresi P, Stratta F, Stefani A, and Bernardi G. Effects of dihydropyridine calcium antagonists on rat midbrain dopaminergic neurones. Br J Pharmacol 113: 831-838, 1994. (Pubitemid 24326822)
79. Moore DJ, West AB, Dawson VL, and Dawson TM. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 28: 57-87, 2005. (Pubitemid 41098899)
80. 2\+ mobilization in dopamine neurons. J Neurosci 23: 149-157, 2003. (Pubitemid 36050414)
81. Mosharov EV, Larsen KE, Kanter E, Phillips KA, Wilson K, Schmitz Y, Krantz DE, Kobayashi K, Edwards RH, and Sulzer D. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 62: 218-229, 2009.
82. Murchison D and Griffith WH. Calcium buffering systems and calcium signaling in aged rat basal forebrain neurons. Aging Cell 6: 297-305, 2007. (Pubitemid 46785135)
83. Murchison D and Griffith WH. Low-voltage activated calcium currents increase in basal forebrain neurons from aged rats. J Neurophysiol 74: 876-887, 1995.
84. Nedergaard S, Flatman JA, and Engberg I. Nifedipine-and omega-conotoxin-sensitive Ca2\+ conductances in guinea-pig substantia nigra pars compacta neurones. J Physiol 466: 727-747, 1993. (Pubitemid 23225251)
85. Nicholls DG. Oxidative stress and energy crises in neuronal dysfunction. Ann N Y Acad Sci 1147: 53-60, 2008.
86. Olanow CW, Gracies JM, Goetz CG, Stoessl AJ, Freeman T, Kordower JH, Godbold J, and Obeso JA. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Mov Disord 24: 336-343, 2009.
87. Orrenius S, Zhivotovsky B, and Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol 4: 552-565, 2003. (Pubitemid 36773407)
88. Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, Klose J, and Shen J. Mitochondrial dysfunction and oxidative damage in parkindeficient mice. J Biol Chem 279: 18614-18622, 2004. (Pubitemid 38623283)
89. Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim JM, and Chung J. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441: 1157-1161, 2006. (Pubitemid 43990737)
90. Pignatelli A, Ackman JB, Vigetti D, Beltrami AP, Zucchini S, and Belluzzi O. A potential reservoir of immature dopaminergic replacement neurons in the adult mammalian olfactory bulb. Pflugers Arch 457: 899-915, 2009.
91. Pignatelli A, Kobayashi K, Okano H, and Belluzzi O. Functional properties of dopaminergic neurones in the mouse olfactory bulb. J Physiol 564: 501-514, 2005. (Pubitemid 40585049)
92. Ping HX and Shepard PD. Apamin-sensitive Ca(2\+)-activated K\+ channels regulate pacemaker activity in nigral dopamine neurons. Neuroreport 7: 809-814, 1996.
93. Pinton P, Rimessi A, Marchi S, Orsini F, Migliaccio E, Giorgio M, Contursi C, Minucci S, Mantovani F, Wieck-owski MR, Del Sal G, Pelicci PG, and Rizzuto R. Protein kinase C beta and prolyl isomerase 1 regulate mitochondrial effects of the life-span determinant p66Shc. Science 315: 659-663, 2007. (Pubitemid 46214712)
94. Postuma RB, Lang AE, Massicotte-Marquez J, and Mon-tplaisir J. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 66: 845-851, 2006. (Pubitemid 43739758)
95. Przedborski S, Tieu K, Perier C, and Vila M. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J Bioenerg Biomembr 36: 375-379, 2004. (Pubitemid 39619844)
96. Puopolo M, Raviola E, and Bean BP. Roles of subthreshold calcium current and sodium current in spontaneous firing of mouse midbrain dopamine neurons. J Neurosci 27: 645-656, 2007. (Pubitemid 46143768)
97. Putzier I, Kullmann PH, Horn JP, and Levitan ES. Cav1.3 channel voltage dependence, not Ca2\+ selectivity, drives pacemaker activity and amplifies bursts in nigral dopamine neurons. J Neurosci 29: 15414-15419, 2009.
98. Reeve AK, Krishnan KJ, and Turnbull DM. Age related mitochondrial degenerative disorders in humans. Biotechnol J 3: 750-756, 2008.
99. Riederer P and Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 38: 277-301, 1976.
100. Ritz B, Qian L, Rhodes SL, Schernhammer E, Olsen J, and Friis S. L-Type calcium channel blockers and Parkinson's disease in Denmark. Ann Neurol 67:600-606, 2010.
101. Rizzuto R. Intracellular Ca(2\+) pools in neuronal signalling. Curr Opin Neurobiol 11: 306-311, 2001. (Pubitemid 32524095)
102. Romo R and Schultz W. Dopamine neurons of the monkey midbrain: contingencies of responses to active touch during self-initiated arm movements. J Neurophysiol 63: 592-606, 1990. (Pubitemid 20115486)
103. Saper CB, Sorrentino DM, German DC, and de Lacalle S. Medullary catecholaminergic neurons in the normal human brain and in Parkinson's disease. Ann Neurol 29: 577-584, 1991.
104. Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 7: 97-109, 2008. (Pubitemid 350251942)
105. Schultz W. Multiple dopamine functions at different time courses. Annu Rev Neurosci 30: 259-288, 2007. (Pubitemid 47218758)
106. Shults CW, Haas RH, Passov D, and Beal MF. Coenzyme Q10 levels correlate with the activities of complexes I and II=III in mitochondria from parkinsonian and non-parkinsonian subjects. Ann Neurol 42: 261-264, 1997. (Pubitemid 27340475)
107. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, and Striessnig J. Expression and 1,4-dihydropyridine- binding properties of brain L-type calcium channel isoforms. Mol Pharmacol 75: 407-414, 2009.
108. Sonsalla PK, Albers DS, and Zeevalk GD. Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism. Amino Acids 14: 69-74, 1998. (Pubitemid 28051154)
109. Stark AK and Pakkenberg B. Histological changes of the dopaminergic nigrostriatal system in aging. Cell Tissue Res 318: 81-92, 2004. (Pubitemid 39362629)
110. Stevens DR and Haas HL. Calcium-dependent pre-potentials contribute to spontaneous activity in rat tuber-omammillary neurons. J Physiol 493 (Pt 3): 747-754, 1996. (Pubitemid 26232110)
111. 2\+ channel isoforms for brain function. Biochem Soc Trans 34: 903-909, 2006. (Pubitemid 44796447)
112. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci 30: 244-250, 2007. (Pubitemid 46667168)
113. Taddese A and Bean BP. Subthreshold sodium current from rapidly inactivating sodium channels drives spontaneous firing of tuberomammillary neurons. Neuron 33: 587-600, 2002. (Pubitemid 34188434)
114. Takakusaki K and Kitai ST. Ionic mechanisms involved in the spontaneous firing of tegmental pedunculopontine nucleus neurons of the rat. Neuroscience 78: 771-794, 1997. (Pubitemid 27179658)
115. Tanner CM, Ross GW, Jewell SA, Hauser RA, Jankovic J, Factor SA, Bressman S, Deligtisch A, Marras C, Lyons KE, Bhudhikanok GS, Roucoux DF, Meng C, Abbott RD, and Langston JW. Occupation and risk of parkinsonism: a mul-ticenter case-control study. Arch Neurol 66: 1106-1113, 2009.
116. Tansey MG and Goldberg MS. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37: 510-518, 2010.
117. Teismann P and Schulz JB. Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res 318: 149-161, 2004. (Pubitemid 39362635)
118. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V, and Przedborski S. Cycloox-ygenase-2 is instrumental in Parkinson's disease neurode-generation. Proc Natl Acad Sci USA 100: 5473-5478, 2003. (Pubitemid 36542729)
119. Teismann P, Tieu K, Cohen O, Choi DK, Wu DC, Marks D, Vila M, Jackson-Lewis V, and Przedborski S. Pathogenic role of glial cells in Parkinson's disease. Mov Disord 18: 121-129, 2003. (Pubitemid 36305454)
120. Tepper JM, Sawyer SF, and Groves PM. Electrophysiologically identified nigral dopaminergic neurons in-tracellularly labeled with HRP: light-microscopic analysis. J Neurosci 7: 2794-2806, 1987.
121. Thannickal TC, Lai YY, and Siegel JM. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 130: 1586-1595, 2007. (Pubitemid 47355933)
122. Travagli RA and Gillis RA. Hyperpolarization-activated currents, IH and IKIR, in rat dorsal motor nucleus of the vagus neurons in vitro. J Neurophysiol 71: 1308-1317, 1994.
123. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 39: 359-407, 2005. (Pubitemid 43011120)
124. Williams JT, North RA, Shefner SA, Nishi S, and Egan TM. Membrane properties of rat locus coeruleus neurones. Neuroscience 13: 137-156, 1984. (Pubitemid 14033088)
125. Wilson CJ and Callaway JC. Coupled oscillator model of the dopaminergic neuron of the substantia nigra. J Neurophysiol 83: 3084-3100, 2000. (Pubitemid 30321496)
126. Yamanaka A, Beuckmann CT, Willie JT, Hara J, Tsujino N, Mieda M, Tominaga M, Yagami K, Sugiyama F, Goto K, Yanagisawa M, and Sakurai T. Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron 38: 701-713, 2003. (Pubitemid 36694778)
127. Zweifel LS, Parker JG, Lobb CJ, Rainwater A, Wall VZ, Fadok JP, Darvas M, Kim MJ, Mizumori SJ, Paladini CA, Phillips PE, and Palmiter RD. Disruption of NMDAR-dependent burst firing by dopamine neurons provides selective assessment of phasic dopamine-dependent behavior. Proc Natl Acad Sci USA 106: 7281-7288, 2009.